Citigroup initiated coverage on Candel Therapeutics with a new price target

2/20/25 6:59:49 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Citigroup initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $25.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CADL

Date	Price Target	Rating	Analyst
2/20/2025	$25.00	Buy	Citigroup
2/19/2025	$20.00	Buy	Canaccord Genuity
2/7/2025	$15.00	Buy	BofA Securities
12/2/2022	$11.00	Buy	H.C. Wainwright
11/19/2021	$18.00	Outperform	BMO Capital
8/23/2021	$9.00	Buy	UBS
8/23/2021	$22.00	Buy	Jefferies
8/23/2021	$15.00	Outperform	Credit Suisse